INTRODUCTION: Studies indicate that chronic treatment with mucoactive drugs may reduce COPD exacerbation rates. This real-world, multicenter, prospective, observational study aimed to determine the effect of long-term mucoactive treatment on exacerbations in patients with COPD in the Czech Republic. METHODS: 452 adult patients on the Czech Multicenter Research Database of COPD with post-bronchodilator FEV1 ≤ 60% of predicted value received standard of care and were followed up for 5 years. For the first 24 months, 81 patients received regular thiol-based mucoactive drugs (77 erdosteine, 4 N-acetylcysteine) at the discretion of the treating physician and 371 patients had no mucoactive treatment (control group). Erdosteine was fully reimbursed, and NAC was partially reimbursed for COPD patients. The annual number/rate of COPD exacerbations over 5 years was monitored. RESULTS: Patients receiving mucoactive treatment for 24 months had a significantly larger reduction from baseline in all exacerbations compared to the control group (- 0.61 vs - 0.18, p = 0.026; - 0.54 vs - 0.09, p = 0.007; - 0.55 vs 0.04, p = 0.005; - 0.67 vs 0.13, p = 0.002; - 0.53 vs 0.10, p = 0.019 in the first to fifth year, respectively). The reduction in moderate exacerbations was also significantly larger in those receiving mucoactive treatment versus no mucoactive treatment. The exacerbation rate was reduced to a greater extent in the subgroups with cough or with stage 3‒4 COPD who received mucoactive treatment but was independent of the use of inhaled corticosteroids (ICS). CONCLUSION: Mucoactive treatment for two years reduced the number of COPD exacerbations (all, moderate) over five years of follow-up. The reduction in exacerbations was more pronounced in patients with cough or with stage 3‒4 COPD but was independent of the use of ICS.

Department of Pneumology University Hospital Hradec Kralove Czech Republic

Department of Pulmonary Diseases and Tuberculosis Masaryk University Brno Czech Republic

Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic

Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Faculty of Medicine in Hradec Kralove Charles University Prague Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

Institute of Pharmaceutical Science King's College London London UK

See more in PubMed

Global Initiative for Chronic Obstructive Lung Disease (2025) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. https://goldcopd.org/goldreports/. Accessed 9 Nov 2024

Balsamo R, Lanata L, Egan NN (2010) Mucoactive drugs. Eur Respir Rev 19(116):127–133. 10.1183/09059180.00003510 PubMed PMC

Tian PW, Wen FQ (2015) Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease. J Transl Int Med 3(3):89–92. 10.1515/jtim-2015-0013 PubMed PMC

Hocquigny A, Hugerot H, Ghanem R, Haute T, Laurent V, Cogulet V, Montier T (2024) Mucoactive drugs and multiple applications in pulmonary disease therapy. Eur J Pharm Biopharm 194:110–117. 10.1016/j.ejpb.2023.12.001 PubMed

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG (2019) Thiol-based drugs in pulmonary medicine: much more than mucolytics. Trends Pharmacol Sci 40(7):452–463. 10.1016/j.tips.2019.04.015 PubMed

Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG (2020) Multifaceted beneficial effects of erdosteine: more than a mucolytic agent. Drugs 80:1799–1809. 10.1007/s40265-020-01412-x PubMed PMC

Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS, PANTHEON study group (2014) Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2:187–194. 10.1016/S2213-2600(13)70286-8 PubMed

Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, Pozzi E, Calverley PMA (2017) Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J 50:1700711. 10.1183/13993003.00711-2017 PubMed PMC

Calverley PMA, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA (2019) Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int J Chron Obstruc Pulmon Dis 14:2733–2744. 10.2147/COPD.S221852 PubMed PMC

Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA (2022) The effect of maintenance treatment with erdosteine on exacerbation treatment and health status in patients with COPD: a post-hoc analysis of the RESTORE dataset. Int J Chron Obstruct Pulmon Dis 17:1909–1920. 10.2147/COPD.S369804 PubMed PMC

Zhou Y, Wu F, Shi Z, Cao J, Tian J, Yao W, Wei L, Li F, Cai S, Shen Y, Wang Z, Zhang H, Chen Y, Fu Y, He Z, Chang C, Jiang Y, Chen S, Yang C, Yu S, Tian H, Cheng Q, Zhao Z, Ying Y, Zhou Y, Liu S, Deng Z, Huang P, Zhang Y, Luo X, Zhao H, Gui J, Lai W, Hu G, Liu C, Su L, Liu Z, Huang J, Zhao D, Zhong N, Ran P, China N-acetylcysteine in Mild-to-moderate COPD Study Group (2024) Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial. Nat Commun 15(1):8468. 10.1038/s41467-024-51079-1 PubMed PMC

Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, Blasi F (2016) A review of national guidelines for management of COPD in Europe. Eur Respir J 47(2):625–637. 10.1183/13993003.01170-2015 PubMed PMC

Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Riesco JA, Simonet P, Rigau D, Soriano JB, Ancochea J (2017) Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease. Guía espanola de la EPOC (GesEPOC) 2017. Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol 53:324–335 PubMed

Miravitlles M, Calle M, Molina J, Almagro P, Gómez J-T, Trigueros JA, Cosío BG, Casanova C, López-Campo JL, Riesco JA, Simonet P, Rigau D, Soriano JB, Ancochea J, Soler-Cataluna JJ (2022) Spanish COPD guidelines (GesEPOC) 2021 Updated pharmacological treatment of stable COPD. Actualización 2021 de la Guía Espanola de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol 58:69–81 PubMed

Kankaanranta H, Harju T, Kilpeläinen M, Mazur W, Lehto JT, Katajisto M, Peisa T, Meinander T, Lehtimäki L (2015) Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the Finnish guidelines. Basic Clin Pharmacol Toxicol 116(4):291–307. 10.1111/bcpt.12366 PubMed PMC

Vogelmeier C, Buhl R, Burghuber O, Criée C-P, Ewig S, Godnic-Cvar J, Hartl S, Herth F, Kardos P, Kenn K, Nowak D, Rabe KF, Studnicka M, Watz H, Welte T, Windisch W, Worth H (2018) Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD) herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. und der Deutschen Atemwegsliga e.V., unter Beteiligung der Österreichischen Gesellschaft für Pneumologie. guideline for the diagnosis and treatment of COPD patients issued by the german respiratory society and the German Atemwegsliga in cooperation with the Austrian Society of pneumology. Pneumologie 72:253–308. 10.1055/s-0043-125031 PubMed

Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatloukal J, Zak J, Sedlak V, Kocianova J, Zatloukal J, Hejduk K, Pracharova S (2013) Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 157(2):189–201. 10.5507/bp.2013.039 PubMed

Zatloukal J, Brat K, Neumannova K, Volakova E, Hejduk K, Kudela O, Kopecky M, Plutinsky M, Koblizek V (2020) Chronic obstructive pulmonary disease – diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 164(4):325–356. 10.5507/bp.2020.056 PubMed

Novotna B, Koblizek V, Zatloukal J, Plutinsky M, Hejduk K, Zbozinkova Z, Jarkovsky J, Sobotik O, Dvorak T, Safranek P (2014) Czech multicenter research database of severe COPD. Int J Chron Obstruct Pulmon Dis 9:1265–1274. 10.2147/COPD.S71828 PubMed PMC

Agusti A (2014) The path to personalised medicine in COPD. Thorax 69(9):857–864. 10.1136/thoraxjnl-2014-205507 PubMed

Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, Humbert M, Jones P, Gibson PG, Vestbo J, Beasley R, Pavord ID (2016) Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47(2):410–419. 10.1183/13993003.01359-2015 PubMed

Cazzola M, Page CP, Wedzicha JA, Celli BR, Anzueto A, Matera MG (2023) Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD. Respir Res 24(1):194. 10.1186/s12931-023-02500-8 PubMed PMC

Calverley P, Pauwels Dagger R, Löfdahl CG, Svensson K, Higenbottam T, Carlsson LG, Ståhl E (2005) Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J 26(3):406–413. 10.1183/09031936.05.00143404 PubMed

Landt EM, Çolak Y, Nordestgaard BG, Lange P, Dahl M (2024) Chronic cough associated with COPD exacerbation, pneumonia and death in the general population. ERJ Open Res 10(1):00697–02023. 10.1183/23120541.00697-2023 PubMed PMC

Diaz AA, Orejas JL, Grumley S, Nath HP, Wang W, Dolliver WR, Yen A, Kligerman SJ, Jacobs K, Manapragada PP, Abozeed M, Aziz MU, Zahid M, Ahmed AA, Terry NL, Estépar RSJ, Kim V, Make BJ, Han MK, Sonavane S, Washko GR, Cho M, Estépar RSJ (2023) Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease. JAMA 329(21):1832–1839. 10.1001/jama.2023.2065 PubMed PMC